



Mersana Therapeutics to Participate in Four Upcoming Conferences

February 27, 2012

Mersana Therapeutics, a company that engineers novel drug conjugates that maximize the potential of new and established therapeutic classes, today announced its participation in four upcoming conferences:

Timothy B. Lowinger, PhD, Chief Scientific Officer, will present "Creating Next Generation ADCs – Enabling New Payload Classes and More Efficient Delivery" at IBC's 28th International Antibody Development & Production Conference on March 2, 2012, at 11:15am at the Hilton Bayfront in San Diego, CA.

Michael A. Metzger, EVP and Chief Operating Officer, will participate in a panel session on, "Platforms: Early Commercial Insights" at the 2012 Annual Meeting of the Massachusetts Biotechnology Council on March 26, 2012, at 2:15pm at the Royal Sonesta Hotel in Cambridge, MA.

Timothy B. Lowinger, PhD, will present in a poster session at the 2012 Annual Meeting of the American Association of Cancer Research (AACR) taking place March 31 – April 4, 2012, at McCormick Place in Chicago, IL. Temporary Abstract #7246 "Polyacetal-based immunoconjugates: Next-generation ADCs with high drug loading, alternative payloads, and alternative protein recognition scaffolds" will be presented on April 3rd from 1:00pm – 5:00pm in Hall F, Poster Section 28.

Timothy B. Lowinger, PhD, will present "Next-generation Antibody Drug Conjugates: Diverse Payloads, Higher Drug Loading, and Alternative Targeting Moieties" at Informa Life Sciences' Antibody Drug Conjugate Conference being held June 13 – 14, 2012, at the Hotel Palace in Berlin, Germany.

About Mersana Therapeutics, Inc.

Mersana engineers novel drug conjugates that maximize the potential of new and established therapeutic classes. Our technology harnesses the power and synergy of nanotechnology, biologics and small molecules. Mersana is advancing its own pipeline of next-generation drugs with best-in-class potential to address multiple unmet needs in oncology. Our versatile conjugation system integrates Fleximer®, a clinically validated biodegradable polymer, with a broad array of customizable linker chemistries matched to therapeutic payloads. Our technology is being leveraged in multiple therapeutic areas through partnerships. www.mersana.com

Media Contact:

MacDougall Biomedical Communications
Jennifer Conrad
[781-235-3060](tel:781-235-3060)
jconrad@machiocom.com